Fig. 1 · Structure

Documents & Downloads

LY2090314

Cat. No. A12741 CAS 603288-22-8

GSK-3 inhibitor

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) which plays an important role in many pathways, including initiation of protein synthesis, cell proliferation, cell differentiation, and apoptosis.

In Stock

Publications for LY2090314

1 publication citing this product

  1. Yuki Shimizu, .et al. , NPJ Precis Oncol, 2022, Mar 17;6(1):16 PMID: 35301419

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

LY2090314 inhibited recombinant human GSK3α and GSK3β, with reported cell-free IC50 values of 1.5 nM and 0.9 nM, respectively. These values describe enzyme-assay potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
GSK-3β 0.9 nM
GSK-3α 1.5 nM

LY2090314 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of LY2090314 from 3 published references. In vitro models include A375 human melanoma cells.

LY2090314 In Vitro Studies

In A375 melanoma cells, 20 nM LY2090314 increased total β-catenin and Axin2 protein in a 0–8 h immunoblot time course. This qualitative downstream response does not quantify cellular target occupancy. [1]

In lorlatinib-intermediate-resistant JFCR-028-3 derivatives, adding 30 nM LY2090314 lowered viability relative to lorlatinib alone after 72 h. The parental cells showed no reported change in lorlatinib sensitivity with the combination, demonstrating model-dependent activity. [2]

Recombinant GSK3 inhibition

Biochemical assay · Human recombinant GSK3α and GSK3β in a cell-free peptide-substrate assay [1]

Reported IC50 values establish nanomolar enzyme inhibition; they are assay endpoints rather than cell-treatment concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Human recombinant GSK3α inhibitionIC50 1.5 nM[1]
Human recombinant GSK3β inhibitionIC50 0.9 nM[1]

Literature-Reported Treatment Conditions

Method
Recombinant enzyme plus phosphorylated peptide substrate; method refers to Engler et al. (2004).
Reported limits
The 2015 assay paragraph does not specify the concentration series, ATP concentration, incubation duration, vehicle, replicate count or normalization/control details. Referenced 2004 full text was not retrieved; no conditions were borrowed.
Methods and source locations

Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314

Evidence concerns the named compound and reported experimental material; no Adooq lot or formulation validation.

Materials and Methods: GSK3 biochemical assay; Results sec017, first paragraph; Fig 1A

Human recombinant GSK3α inhibition: Cell-free recombinant kinase assay with a phosphorylated peptide substrate. — Results sec017, first paragraph

Human recombinant GSK3β inhibition: Same reported assay framework, tested with the β isoform. — Results sec017, first paragraph

Protein response to LY2090314 in A375 melanoma cells

Cell-based study · A375 human melanoma cells [1]

A time-course immunoblot showed increased total β-catenin and Axin2 protein after LY2090314 exposure relative to the zero-time sample.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total β-catenin and Axin2 protein abundanceQualitative immunoblot response Increased following treatment; no fold change extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM
Exposure duration
0, 0.5, 1, 2, 4 and 8 h, as labeled in Fig 1C
Method
Cell treatment followed by immunoblotting.
Co-treatment
Single-agent LY2090314
Reported limits
Fig 1C does not state an independent replicate count or quantified uncertainty; vehicle identity for this panel is not specified. Zero-time is the depicted comparator, not a stated time-matched vehicle series.
Methods and source locations

Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314

Evidence concerns the named compound and reported experimental material; no Adooq lot or formulation validation.

Fig 1C image/caption; Results sec017; Materials and Methods: Immunoblotting and Reagents

Total β-catenin and Axin2 protein abundance: Western blot with GAPDH loading control and zero-time comparison. — Fig 1C image/caption and Results sec017

LY2090314 plus lorlatinib in parental and resistant lung cancer cells

Cell-based study · JFCR-028-3 parental cells and lorlatinib-intermediate-resistant derivatives LR1000#1, LR1000#2 and LR3000 [2]

Adding a fixed concentration of LY2090314 to lorlatinib lowered viability in resistant derivatives relative to lorlatinib alone. The authors reported no difference in lorlatinib sensitivity in parental cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative cell viability (% of control)Concentration-response comparison Lower viability with the combination in resistant derivatives; parental sensitivity reported unchanged. Mean ± SD, n = 3 replicates.[2]

Literature-Reported Treatment Conditions

Treatment concentration
LY2090314 fixed at 30 nM with a lorlatinib concentration series, as labeled in Fig 3b–e.
Exposure duration
72 h
Method
CellTiter-Glo luminescence viability assay; cells seeded in triplicate.
Vehicle
DMSO used to dissolve LY2090314 and lorlatinib; final vehicle percentage not specified in the read section.
Co-treatment
LY2090314 plus lorlatinib, compared with lorlatinib alone.
Reported limits
Caption identifies three replicates without establishing independent biological repeats. Exact potency estimates and combination statistics are not tabulated for these panels.
Methods and source locations

Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314

Supplier attribution supports reported AdooQ use, without establishing SKU or lot equivalence.

Fig 3b–e image/caption; Results Sec4; Methods: Reagents and Cell viability assay

Relative cell viability (% of control): CellTiter-Glo after 72 h; no numerical IC50 or exact curve values inferred. — Fig 3b–e image/caption; Results Sec4

LY2090314 In Vivo Studies

In female NSG mice bearing Hep3B xenografts, LY2090314 plus FIDAS-5 reduced endpoint tumor volume relative to FIDAS-5 alone (P = 0.02). The corresponding tumor-weight comparison was not statistically significant (P = 0.07), limiting the consistency of the combination effect across endpoints. [3]

LY2090314 with FIDAS-5 in Hep3B xenografts

Animal study · Female NSG mice bearing subcutaneous Hep3B human liver cancer xenografts [3]

A combination regimen produced greater tumor-volume suppression than FIDAS-5 alone in this xenograft design. The corresponding tumor-weight comparison was not statistically significant. This does not establish a general single-agent or survival benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
End point Hep3B xenograft tumor volume: combination versus FIDAS-5 aloneReported comparison P value P = 0.02; lower volume with combination. No exact mean volume digitized.[3]
End point Hep3B xenograft tumor weight: combination versus FIDAS-5 aloneReported comparison P value P = 0.07; difference did not meet the stated P < 0.05 criterion.[3]

Conditions shared by the study groups

Treatment course
Drug treatment described for 7 days; tumor-volume time course shown through day 12 after treatment initiation.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle and both single-agent groups were included.Reference tumor-growth group. n = 5 female mice.[3]
LY2090314 alone
2.5 mg/kg LY2090314
Vehicle and both single-agent groups were included.Single-agent comparator; no independent exact efficacy estimate or significance claim extracted. n = 6 female mice.[3]
FIDAS-5 alone
10 mg/kg FIDAS-5
Vehicle and both single-agent groups were included.Single-agent comparator for addition of LY2090314. n = 6 female mice.[3]
LY2090314 plus FIDAS-5
2.5 mg/kg LY2090314 plus 10 mg/kg FIDAS-5
Vehicle and both single-agent groups were included.Lower endpoint volume versus FIDAS-5 alone (P = 0.02), while endpoint weight comparison was P = 0.07. n = 7 female mice.[3]
Vehicle control
Model: Female NSG mice bearing subcutaneous Hep3B human liver cancer xenografts
Vehicle: Corn oil or 40% (vol/vol) PEG400 vehicles are described; whether both were co-administered to each control mouse is not explicit.
Reported limits: Injection route and dosing frequency are not specified in the acquired Mouse experiments paragraph. The 7-day course and 12-day plotted follow-up are recorded separately; no daily schedule inferred.
LY2090314 alone
Model: Female NSG mice bearing subcutaneous Hep3B human liver cancer xenografts
Vehicle: 40% (vol/vol) PEG400
Reported limits: Injection route and dosing frequency are not specified in the acquired Mouse experiments paragraph. The 7-day course and 12-day plotted follow-up are recorded separately; no daily schedule inferred.
FIDAS-5 alone
Model: Female NSG mice bearing subcutaneous Hep3B human liver cancer xenografts
Vehicle: Corn oil
Reported limits: Injection route and dosing frequency are not specified in the acquired Mouse experiments paragraph. The 7-day course and 12-day plotted follow-up are recorded separately; no daily schedule inferred.
LY2090314 plus FIDAS-5
Model: Female NSG mice bearing subcutaneous Hep3B human liver cancer xenografts
Vehicle: LY2090314 in 40% (vol/vol) PEG400; FIDAS-5 in corn oil
Reported limits: Injection route and dosing frequency are not specified in the acquired Mouse experiments paragraph. The 7-day course and 12-day plotted follow-up are recorded separately; no daily schedule inferred.
Methods and source locations

Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314

Compound-level mouse xenograft evidence for the reported supplier material and combination; no Adooq lot validation.

Fig 6b (Hep3B); Extended Data Fig 9b–d (Hep3B); Methods: Mouse experiments; In vitro drug treatment; Statistics & Reproducibility

End point Hep3B xenograft tumor volume: combination versus FIDAS-5 alone: Two-tailed Student’s t-test per figure caption; mean ± s.e.m.; animal group sizes reported separately. — Extended Data Fig 9c, Hep3B plot and caption

End point Hep3B xenograft tumor weight: combination versus FIDAS-5 alone: Two-tailed Student’s t-test per figure caption; mean ± s.e.m.; animal group sizes reported separately. — Extended Data Fig 9b, Hep3B plot and caption

Vehicle control · Fig 6b (Hep3B); Extended Data Fig 9b–d (Hep3B); Methods: Mouse experiments; In vitro drug treatment; Statistics & Reproducibility

LY2090314 alone · Fig 6b (Hep3B); Extended Data Fig 9b–d (Hep3B); Methods: Mouse experiments; In vitro drug treatment; Statistics & Reproducibility

FIDAS-5 alone · Fig 6b (Hep3B); Extended Data Fig 9b–d (Hep3B); Methods: Mouse experiments; In vitro drug treatment; Statistics & Reproducibility

LY2090314 plus FIDAS-5 · Fig 6b (Hep3B); Extended Data Fig 9b–d (Hep3B); Methods: Mouse experiments; In vitro drug treatment; Statistics & Reproducibility

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 603288-22-8
Applications GSK-3 inhibitor
Formula C28H25FN6O3
Molecular Weight 512.53
SMILES
C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (181.45 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (3.9 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
16 mg/mL
Vehicle
5% DMSO+45% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY2090314 Research References

  1. [1] Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3 PLOS ONE (2015). PMID: 25915038 DOI: 10.1371/journal.pone.0125028 Source material
  2. [2] Yuki Shimizu, Koutaroh Okada, Jun Adachi, et al. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer npj Precision Oncology (2022). PMID: 35301419 DOI: 10.1038/s41698-022-00260-0 Source material
  3. [3] Fuming Li, Pingyu Liu, Wen Mi, et al. Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer Nature Cancer (2024). PMID: 38168934 DOI: 10.1038/s43018-023-00671-3 Source material

Publications

1 publication citing this product

  1. Yuki Shimizu, .et al. , NPJ Precis Oncol, 2022, Mar 17;6(1):16 PMID: 35301419

Added to your cart

View Cart Checkout
Loading...